LSIPR Article - The Value of Secrecy for Big Pharma
01 July 2016
Andrew Sanderson and Ling Zhuang write for the Life Sciences Intellectual Property Review.
While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments.
To read the full article, please click here